skip to main content
DOE PAGES title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Ligand-targeted theranostic nanomedicines against cancer

Abstract

Nanomedicines have significant potential for cancer treatment. Although the majority of nanomedicines currently tested in clinical trials utilize simple, biocompatible liposome-based nanocarriers, their widespread use is limited by non-specificity and low target site concentration and thus, do not provide a substantial clinical advantage over conventional, systemic chemotherapy. In the past 20 years, we have identified specific receptors expressed on the surfaces of tumor endothelial and perivascular cells, tumor cells, the extracellular matrix and stromal cells using combinatorial peptide libraries displayed on bacteriophage. These studies corroborate the notion that unique receptor proteins such as IL-11Rα, GRP78, EphA5, among others, are differentially overexpressed in tumors and present opportunities to deliver tumor-specific therapeutic drugs. By using peptides that bind to tumor-specific cell-surface receptors, therapeutic agents such as apoptotic peptides, suicide genes, imaging dyes or chemotherapeutics can be precisely and systemically delivered to reduce tumor growth in vivo, without harming healthy cells. Given the clinical applicability of peptide-based therapeutics, targeted delivery of nanocarriers loaded with therapeutic cargos seems plausible. We propose a modular design of a functionalized protocell in which a tumor-targeting moiety, such as a peptide or recombinant human antibody single chain variable fragment (scFv), is conjugated to a lipid bilayer surrounding amore » silica-based nanocarrier core containing a protected therapeutic cargo. The functionalized protocell can be tailored to a specific cancer subtype and treatment regimen by exchanging the tumor-targeting moiety and/or therapeutic cargo or used in combination to create unique, theranostic agents. In this review, we summarize the identification of tumor-specific receptors through combinatorial phage display technology and the use of antibody display selection to identify recombinant human scFvs against these tumor-specific receptors. We compare the characteristics of different types of simple and complex nanocarriers, and discuss potential types of therapeutic cargos and conjugation strategies. As a result, the modular design of functionalized protocells may improve the efficacy and safety of nanomedicines for future cancer therapy.« less

Authors:
; ; ; ; ; ; ; ; ; ; ; ;
Publication Date:
Research Org.:
Sandia National Lab. (SNL-NM), Albuquerque, NM (United States)
Sponsoring Org.:
USDOE National Nuclear Security Administration (NNSA)
OSTI Identifier:
1236080
Alternate Identifier(s):
OSTI ID: 1249086
Report Number(s):
SAND-2016-3040J
Journal ID: ISSN 0168-3659; S0168365916300025; PII: S0168365916300025
Grant/Contract Number:  
AC04-94AL85000
Resource Type:
Published Article
Journal Name:
Journal of Controlled Release
Additional Journal Information:
Journal Name: Journal of Controlled Release Journal Volume: 240 Journal Issue: C; Journal ID: ISSN 0168-3659
Publisher:
Elsevier
Country of Publication:
Netherlands
Language:
English
Subject:
60 APPLIED LIFE SCIENCES; antibody display; phage display; peptide ligands; protocells; tumor targeting

Citation Formats

Yao, Virginia J., D'Angelo, Sara, Butler, Kimberly S., Theron, Christophe, Smith, Tracey L., Marchiò, Serena, Gelovani, Juri G., Sidman, Richard L., Dobroff, Andrey S., Brinker, C. Jeffrey, Bradbury, Andrew R. M., Arap, Wadih, and Pasqualini, Renata. Ligand-targeted theranostic nanomedicines against cancer. Netherlands: N. p., 2016. Web. https://doi.org/10.1016/j.jconrel.2016.01.002.
Yao, Virginia J., D'Angelo, Sara, Butler, Kimberly S., Theron, Christophe, Smith, Tracey L., Marchiò, Serena, Gelovani, Juri G., Sidman, Richard L., Dobroff, Andrey S., Brinker, C. Jeffrey, Bradbury, Andrew R. M., Arap, Wadih, & Pasqualini, Renata. Ligand-targeted theranostic nanomedicines against cancer. Netherlands. https://doi.org/10.1016/j.jconrel.2016.01.002
Yao, Virginia J., D'Angelo, Sara, Butler, Kimberly S., Theron, Christophe, Smith, Tracey L., Marchiò, Serena, Gelovani, Juri G., Sidman, Richard L., Dobroff, Andrey S., Brinker, C. Jeffrey, Bradbury, Andrew R. M., Arap, Wadih, and Pasqualini, Renata. Sat . "Ligand-targeted theranostic nanomedicines against cancer". Netherlands. https://doi.org/10.1016/j.jconrel.2016.01.002.
@article{osti_1236080,
title = {Ligand-targeted theranostic nanomedicines against cancer},
author = {Yao, Virginia J. and D'Angelo, Sara and Butler, Kimberly S. and Theron, Christophe and Smith, Tracey L. and Marchiò, Serena and Gelovani, Juri G. and Sidman, Richard L. and Dobroff, Andrey S. and Brinker, C. Jeffrey and Bradbury, Andrew R. M. and Arap, Wadih and Pasqualini, Renata},
abstractNote = {Nanomedicines have significant potential for cancer treatment. Although the majority of nanomedicines currently tested in clinical trials utilize simple, biocompatible liposome-based nanocarriers, their widespread use is limited by non-specificity and low target site concentration and thus, do not provide a substantial clinical advantage over conventional, systemic chemotherapy. In the past 20 years, we have identified specific receptors expressed on the surfaces of tumor endothelial and perivascular cells, tumor cells, the extracellular matrix and stromal cells using combinatorial peptide libraries displayed on bacteriophage. These studies corroborate the notion that unique receptor proteins such as IL-11Rα, GRP78, EphA5, among others, are differentially overexpressed in tumors and present opportunities to deliver tumor-specific therapeutic drugs. By using peptides that bind to tumor-specific cell-surface receptors, therapeutic agents such as apoptotic peptides, suicide genes, imaging dyes or chemotherapeutics can be precisely and systemically delivered to reduce tumor growth in vivo, without harming healthy cells. Given the clinical applicability of peptide-based therapeutics, targeted delivery of nanocarriers loaded with therapeutic cargos seems plausible. We propose a modular design of a functionalized protocell in which a tumor-targeting moiety, such as a peptide or recombinant human antibody single chain variable fragment (scFv), is conjugated to a lipid bilayer surrounding a silica-based nanocarrier core containing a protected therapeutic cargo. The functionalized protocell can be tailored to a specific cancer subtype and treatment regimen by exchanging the tumor-targeting moiety and/or therapeutic cargo or used in combination to create unique, theranostic agents. In this review, we summarize the identification of tumor-specific receptors through combinatorial phage display technology and the use of antibody display selection to identify recombinant human scFvs against these tumor-specific receptors. We compare the characteristics of different types of simple and complex nanocarriers, and discuss potential types of therapeutic cargos and conjugation strategies. As a result, the modular design of functionalized protocells may improve the efficacy and safety of nanomedicines for future cancer therapy.},
doi = {10.1016/j.jconrel.2016.01.002},
journal = {Journal of Controlled Release},
number = C,
volume = 240,
place = {Netherlands},
year = {2016},
month = {10}
}

Journal Article:
Free Publicly Available Full Text
Publisher's Version of Record
https://doi.org/10.1016/j.jconrel.2016.01.002

Citation Metrics:
Cited by: 14 works
Citation information provided by
Web of Science

Save / Share:

Works referencing / citing this record:

Ligand‐Installed Nanocarriers toward Precision Therapy
journal, July 2019

  • Mi, Peng; Cabral, Horacio; Kataoka, Kazunori
  • Advanced Materials, Vol. 32, Issue 13
  • DOI: 10.1002/adma.201902604

Molecular Scaffolds as Double‐Targeting Agents For the Diagnosis and Treatment of Neuroblastoma
journal, January 2019

  • Villaverde, Gonzalo; Alfranca, Arantzazu; Gonzalez‐Murillo, África
  • Angewandte Chemie, Vol. 131, Issue 10
  • DOI: 10.1002/ange.201811691

Molecular Scaffolds as Double‐Targeting Agents For the Diagnosis and Treatment of Neuroblastoma
journal, March 2019

  • Villaverde, Gonzalo; Alfranca, Arantzazu; Gonzalez‐Murillo, África
  • Angewandte Chemie International Edition, Vol. 58, Issue 10
  • DOI: 10.1002/anie.201811691

Nanostructure Empowers Active Tumor Targeting in Ligand‐Based Molecular Delivery
journal, October 2019

  • López‐Laguna, Hèctor; Sala, Rita; Sánchez, Julieta M.
  • Particle & Particle Systems Characterization, Vol. 36, Issue 11
  • DOI: 10.1002/ppsc.201900304

Nanoconfinement-mediated cancer theranostics
journal, January 2020


Establishing the effects of mesoporous silica nanoparticle properties on in vivo disposition using imaging-based pharmacokinetics
journal, October 2018


Polymer–drug conjugate therapeutics: advances, insights and prospects
journal, December 2018

  • Ekladious, Iriny; Colson, Yolonda L.; Grinstaff, Mark W.
  • Nature Reviews Drug Discovery, Vol. 18, Issue 4
  • DOI: 10.1038/s41573-018-0005-0

Antibody fragments as nanoparticle targeting ligands: a step in the right direction
journal, January 2017

  • Richards, Daniel A.; Maruani, Antoine; Chudasama, Vijay
  • Chemical Science, Vol. 8, Issue 1
  • DOI: 10.1039/c6sc02403c

Peptide-based nanoprobes for molecular imaging and disease diagnostics
journal, January 2018

  • Zhang, Pengcheng; Cui, Yonggang; Anderson, Caleb F.
  • Chemical Society Reviews, Vol. 47, Issue 10
  • DOI: 10.1039/c7cs00793k

Peptide and protein nanoparticle conjugates: versatile platforms for biomedical applications
journal, January 2018

  • Spicer, Christopher D.; Jumeaux, Coline; Gupta, Bakul
  • Chemical Society Reviews, Vol. 47, Issue 10
  • DOI: 10.1039/c7cs00877e

Adsorption and fusion of hybrid lipid/polymer vesicles onto 2D and 3D surfaces
journal, January 2018

  • Paxton, Walter F.; McAninch, Patrick T.; Shin, Sun Hae Ra
  • Soft Matter, Vol. 14, Issue 40
  • DOI: 10.1039/c8sm00343b

Antibody-guided nanomedicines as novel breakthrough therapeutic, diagnostic and theranostic tools
journal, January 2019

  • Farahavar, Ghazal; Abolmaali, Samira Sadat; Gholijani, Nasser
  • Biomaterials Science, Vol. 7, Issue 10
  • DOI: 10.1039/c9bm00931k

Multifunctional Gd-based mesoporous silica nanotheranostic for anticancer drug delivery
journal, January 2019

  • Carniato, Fabio; Alberti, Diego; Lapadula, Angelica
  • Journal of Materials Chemistry B, Vol. 7, Issue 19
  • DOI: 10.1039/c9tb00375d

Bacteriophages engineered to display foreign peptides may become short‐circulating phages
journal, April 2019

  • Hodyra‐Stefaniak, Katarzyna; Lahutta, Karolina; Majewska, Joanna
  • Microbial Biotechnology, Vol. 12, Issue 4
  • DOI: 10.1111/1751-7915.13414

Targeting HER2-breast tumors with scFv-decorated bimodal nanoprobes
journal, February 2018

  • Alric, Christophe; Hervé-Aubert, Katel; Aubrey, Nicolas
  • Journal of Nanobiotechnology, Vol. 16, Issue 1
  • DOI: 10.1186/s12951-018-0341-6

Nanotechnology advances towards development of targeted-treatment for obesity
journal, December 2019

  • Sibuyi, Nicole Remaliah Samantha; Moabelo, Koena Leah; Meyer, Mervin
  • Journal of Nanobiotechnology, Vol. 17, Issue 1
  • DOI: 10.1186/s12951-019-0554-3

Aptamers as Delivery Agents of siRNA and Chimeric Formulations for the Treatment of Cancer
journal, December 2019

  • Dinis Ano Bom, Ana Paula; da Costa Neves, Patrícia Cristina; Bonacossa de Almeida, Carlos Eduardo
  • Pharmaceutics, Vol. 11, Issue 12
  • DOI: 10.3390/pharmaceutics11120684

Applying nanotherapeutics to improve chemoradiotherapy treatment for cancer
journal, August 2017